| Abstrakt: |
A recent report from Xihua University in Sichuan, China discusses the role of VEGFR, a receptor tyrosine kinase inhibitor, in promoting angiogenesis and vascular permeability. VEGFR-2, a subtype of VEGFR, is closely related to various cancers and serves as a target for cancer treatments. The report provides an overview of the structure and functions of VEGFR, as well as current VEGFR inhibitors in clinical use. It also summarizes the activities, selectivity, and therapeutic use of VEGFR small molecule inhibitors reported in patents from 2021 to 2023. The research offers insights for the future development of targeted VEGFR inhibitors. [Extracted from the article] |
